> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Weekly R&D and Compliance Ledger: Hengrui's 81% liver-fat drop meets Guangxi dual probes
- URL: https://chinapharmadesk.com/china-pharma-tracker-2026-11-21/
- Published: 2026-11-21T11:29:58.000Z
- Updated: 2026-11-21T11:30:02.000Z
- Description: China Pharma Desk's Nov 21, 2026 ledger covers Hengrui's (600276.SS) 81.0% AASLD liver-fat drop on HRS-4729 (NCT06762600) and herombopag sNDA (CXHS2600158), GenSci161, and CSRC/FDA probes in Guangxi.
- Author: Lin Yi
- Tags: Desk analysis, Pipeline, GLP-1 & Metabolic, Regulation, Hengrui Pharma

Between November 18 and November 21, 2026, domestic statutory filings on `CNINFO`, clinical readouts from the 77th American Association for the Study of Liver Diseases (`AASLD`) Annual Meeting, and newly released U.S. and Chinese regulatory enforcement notices converged across two distinct tracks. On the R&D front, six Chinese drugmakers—led by [Jiangsu Hengrui Pharmaceuticals (SSE: 600276; HKEX: 01276)](https://static.cninfo.com.cn/finalpage/2026-11-21/1225681112.PDF?ref=chinapharmadesk.com), [Changchun High-Tech / GenSci (SZSE: 000661)](https://static.cninfo.com.cn/finalpage/2026-11-21/1225680915.PDF?ref=chinapharmadesk.com), [Huadong Medicine (SZSE: 000963)](https://static.cninfo.com.cn/finalpage/2026-11-18/1225674102.PDF?ref=chinapharmadesk.com), [Hybio Pharmaceutical (SZSE: 300199)](https://static.cninfo.com.cn/finalpage/2026-11-20/1225679182.PDF?ref=chinapharmadesk.com), Simcere Pharmaceutical (`HKEX: 02096`), and [Shenyang Xingqi Ophthalmic (SZSE: 300573)](https://static.cninfo.com.cn/finalpage/2026-11-20/1225680490.PDF?ref=chinapharmadesk.com)—advanced multi-target biologics, `PROTAC` degraders, and `GLP-1/GIP/GCG` triple agonists across metabolic liver disease and rare autoinflammatory disorders. Over the same 48-hour window, two flagship pharmaceutical groups in **Guangxi Province** were hit by severe domestic and U.S. compliance enforcement: [Guangxi Wuzhou Zhongheng Group (SSE: 600252, Notice Lin 2026-97)](https://static.cninfo.com.cn/finalpage/2026-11-21/1225682264.PDF?ref=chinapharmadesk.com) received its second China Securities Regulatory Commission (`CSRC`) warning letter of 2026 (`[2026] No. 23`) over **RMB 796.80 million in restated distribution revenues** and a criminal contract-fraud referral, while Consun Pharmaceutical Group (`HKEX: 01681`) subsidiary **Guangxi Yulin Pharmaceutical** was cited in an **eight-observation U.S. FDA Form 483** for manufacturing U.S.-bound over-the-counter (`OTC`) batches inside a decommissioned formulation tank for seven consecutive months.

This weekend deep-dive dissects the clinical mechanisms, trial architectures, and forensic accounting/cGMP records behind both waves of disclosures.

## Summary matrix: Nine late-week pipeline, generic, and compliance disclosures (Nov 18–21, 2026)

| Company (Ticker)                                                 | Asset / Facility & Filing Code                                                 | Modality / Regulatory Category                                                       | Core Clinical or Enforcement Metric                                                                                                                                                                              | Next Evidence Trigger                                                                        |
| ---------------------------------------------------------------- | ------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------- |
| **Jiangsu Hengrui (600276.SS / 01276.HK)**                       | **HRS-4729** (NCT06762600 Ph1 MAD / NCT07660848 Ph2)                           | Once-weekly SC GLP-1/GIP/GCG triple receptor agonist                                 | **Week 12 mean MRI-PDFF liver fat drop \-81.0% at 8 mg** (vs. \-41.0% placebo) in n=34 MASLD \+ obesity subgroup; up to **100% <5% liver fat normalization**; weight **\-9.7% to \-16.6%**                       | Phase 2 MASH (NCT07660848) biopsy and MRI-PDFF readout                                       |
| **Jiangsu Hengrui (600276.SS / 01276.HK)**                       | **herombopag olamine (Hengqu)** (Lin 2026-182, CXHS2600158)                    | Oral non-peptide TPO-R agonist (5th indication sNDA)                                 | Phase 3 SHR8735-302 (n=127, 21 China centers) met primary endpoint in **CLD thrombocytopenia prior to elective invasive procedures**; cumulative R&D **RMB 668.20m**                                             | NMPA approval decision (2027) vs. avatrombopag (Doptelet) and lusutrombopag (Mulpleta)       |
| **Hybio Pharma (300199.SZ) & Qilu Pharma**                       | **HY3003 Injection** (2026-077, 2026LP03570–03575) & **QLS7402** (NCT07950462) | Once-weekly SC GLP-1R/GIPR/GCGR triple agonist (HY3003) & obesity biologic (QLS7402) | **6 NMPA IND approvals** (CXHL2601095–1100) for HY3003 weekly SC weight management (joining active U.S. FDA IND \+ China oral tablet IND); Qilu registers 140-patient Ph1 for QLS7402                            | Phase 1 human dosing and weight-loss readouts for weekly SC and oral HY3003                  |
| **Changchun High-Tech / GenSci (000661.SZ)**                     | **GenSci161 Injection** (2026-106, CXSL2601287 & CXSL2601288)                  | Class 1 fully human IgG1 bispecific antibody targeting **IL-1α \+ IL-1β**            | NMPA accepted **6th & 7th IND applications** in **pyoderma gangrenosum (PG)** and **CAPS** (FCAS/MWS/NOMID), expanding beyond EM, HS (U.S. + China IND), NIU, CTD-ILD, and RP                                    | 60-working-day CDE implied IND clearance (\~Feb 2027) and Phase 1/2 rare-disease basket data |
| **Huadong Medicine (000963.SZ)**                                 | **HDM4002 Injection** (2026-064, 2026LP03558 / CXSL2600971)                    | Class 1 bispecific antibody targeting **CFB \+ MASP-2**                              | NMPA approved Phase 1 IND in adult **primary IgA nephropathy (IgAN)** to dual-block alternative (CFB) and lectin (MASP-2) complement pathways                                                                    | First-in-human Phase 1 dosing and 24-hour UPCR / eGFR biomarker data                         |
| **Simcere Pharma (02096.HK)**                                    | **SIM0712 Capsules** (Nov 16–20 disclosure)                                    | Oral CRBN\-recruiting **STAT6 PROTAC degrader**                                      | NMPA approved IND for **atopic dermatitis (AD)**; selectively binds STAT6 SH2 domain (sparing STAT1/STAT5) to block IL-4 and IL-13 Type 2 inflammation                                                           | Phase 1 healthy-volunteer and AD patient STAT6 degradation kinetics                          |
| **Shenyang Xingqi (300573.SZ)**                                  | **SQ-25042 Intravitreal Solution** (2026-070, 2026LP03584–03586)               | Class 1 fusion-protein intravitreal biologic                                         | Simultaneous NMPA IND approvals across **nAMD (LP03584)**, **DME (LP03585)**, and **RVO macular edema (LP03586)**                                                                                                | Phase 1 intravitreal dosing and durability intervals vs. faricimab / aflibercept             |
| **Guangxi Wuzhou Zhongheng (600252.SS)**                         | **Subsidiary Guangtou Pharma & Group** (Lin 2026-97 / Lin 2026-58)             | CSRC Guangxi Bureau Warning Letter **\[2026\] No. 23** (Nov 20, 2026)                | Cited for 2023–2025 asset-impairment & revenue errors: **RMB 704.14m gross-to-net cut** \+ **RMB 92.66m reversal on 5 disputed/criminal-referred distribution clients**                                          | Nanning PSB criminal fraud investigation outcome & FY2026 audit opinion                      |
| **Consun (01681.HK) / Guangxi Yulin Pharma & Daiichi Sankyo EU** | **Yulin OTC Plant** (8-item FDA 483) & **Daiichi EU Plant** (3-item FDA 483)   | U.S. FDA cGMP inspection enforcement (21 CFR Part 211)                               | Yulin: **7 months of U.S. OTC production in red-tagged Tank #4**, release without active % assay, QC raw data deletion, **no API vendor audits since 2016**; Daiichi EU: uncontrolled Empower manual integration | Potential FDA Warning Letter or Import Alert 66-40 for Guangxi Yulin Pharmaceutical          |

---

## 1\. Metabolic and liver-hematology expansion: Hengrui’s HRS-4729, herombopag, and Hybio’s HY3003

### HRS-4729 delivers up to 81.0% Week 12 liver defatting at AASLD 2026

Following our [earlier coverage of Boehringer Ingelheim’s survodutide, Novo Nordisk’s semaglutide, and Alnylam’s ALN-CIDEB at AASLD 2026](https://chinapharmadesk.com/aasld-mash-glp1-sirna-split/) and [Hengrui’s HRS-5635 hepatitis B readout](https://chinapharmadesk.com/hengrui-hrs5635-hbsag-phase2/), Hengrui released the full post-hoc subgroup dataset from the oral presentation of its once-weekly subcutaneous `GLP-1/GIP/GCG` triple receptor agonist **`HRS-4729`** (first-in-human Phase 1 trial [NCT06762600](https://clinicaltrials.gov/study/NCT06762600?ref=chinapharmadesk.com), led by Professor Wen Qing and presented by Director He Kun of Jinan Central Hospital).

While `GLP-1` and `GIP` agonism reduce hepatic lipid influx indirectly through systemic weight loss and insulin sensitization, direct activation of hepatic **glucagon (`GCG`) receptors** stimulates mitochondrial *β*\-oxidation and suppresses *de novo* lipogenesis inside hepatocytes. In the multiple-ascending-dose (`MAD`) cohort of `NCT06762600`, **48 overweight or obese adults** (aged 18–55, `BMI 28–40 kg/m²`) were randomized to 12 weeks of once-weekly subcutaneous `HRS-4729` (`1 mg` fixed dose, or titrated to target doses of `4 mg`, `8 mg`, or `12 mg`) or placebo. Among the **34 participants** with baseline metabolic dysfunction-associated steatotic liver disease (`MASLD`, defined as magnetic resonance imaging proton density fat fraction `[MRI-PDFF] >= 5%`):

- **Dose-dependent relative liver fat reduction**: At Week 12, mean percentage change from baseline in `MRI-PDFF` liver fat ranged from **`-41.0%` to `-81.0%`** across `HRS-4729` dose cohorts, peaking at **`-81.0%` in the `8 mg` group** compared with `-41.0%` in the placebo group *(the `12 mg` cohort entered with a lower mean baseline liver fat of `8.5%`, creating a floor effect)*.
- **Higher baseline steatosis yielded deeper clearance**: Among participants with baseline `MRI-PDFF >= 8%` and `>= 10%`, maximum mean relative liver fat reductions reached **`82.6%` and `89.8%`**, respectively.
- **Complete steatosis resolution (`<5%` liver fat)**: Across the `4 mg`, `8 mg`, and `12 mg` titrated cohorts, the proportion of participants achieving ≥ 30%, ≥ 50%, and ≥ 70% relative liver fat reductions reached **up to `100%`**, and **up to `100%` of treated participants** normalized absolute hepatic fat content below the **5% radiographic steatosis threshold**.
- **Anthropometric and safety profile**: Over the same 12-week window, `HRS-4729` reduced mean body weight by **`-9.7%` to `-16.6%`** (versus `-4.8%` for placebo) and shrank waist circumference by **`-8.7` to `-14.8 cm`** (versus `-6.7 cm` for placebo), alongside reductions in triglycerides, total cholesterol, and `LDL-C`. All treatment-emergent adverse events (`TEAEs`) were mild to moderate (predominantly gastrointestinal nausea and vomiting), with **zero serious adverse events (`SAEs`) and zero treatment discontinuations**. Hengrui is already evaluating `HRS-4729` in a dedicated Phase 2 metabolic dysfunction-associated steatohepatitis (`MASH`) trial ([NCT07660848](https://clinicaltrials.gov/study/NCT07660848?ref=chinapharmadesk.com)).

Meanwhile, on November 20, **Hybio Pharmaceutical (`300199.SZ`, Notice `2026-077`)** received six `NMPA` clinical trial approval notices (`2026LP03570` through `2026LP03575`; acceptance numbers `CXHL2601095`–`CXHL2601100`) for its own once-weekly subcutaneous `GLP-1R/GIPR/GCGR` triple agonist **`HY3003` injection** in adult weight management. Hybio is pursuing a three-formulation strategy for `HY3003`—combining the newly cleared China weekly injection (which already holds an active U.S. FDA `IND`), a once-daily oral tablet (`China IND accepted`), and a preclinical monthly extended-release depot—claiming superior weight loss at equimolar doses in diet-induced obese (`DIO`) mice over both dual agonist `tirzepatide` and triple agonist `retatrutide`.

### Herombopag (`CXHS2600158`) targets the peri-procedural CLD thrombocytopenia market

In a separate statutory filing on November 21 (`Lin 2026-182`), Hengrui announced that the `NMPA` accepted a supplemental New Drug Application (`sNDA`, `CXHS2600158`) for its oral non-peptide thrombopoietin receptor (`TPO-R`) agonist **`herombopag olamine` (`Hengqu`)** in adults with chronic liver disease (`CLD`)-associated thrombocytopenia scheduled to undergo elective invasive procedures (including diagnostic procedures).

Backed by **RMB 668.20 million** in cumulative R&D investment, the filing rests on the multicenter, randomized, double-blind, placebo-controlled Phase 3 `**SHR8735-302**` trial (`n=127` across 21 Chinese hospitals led by Professor Zhou Jian at Fudan University Zhongshan Hospital), which met its primary efficacy endpoint in August 2026 by reducing the need for peri-procedural platelet transfusions. Two commercial and clinical details stand out in the filing:

1. **Unifying five `TPO-R` indications under one patented Class 1 tablet**: `Herombopag` is already approved in China across four hematology and oncology indications—chronic primary immune thrombocytopenia (`ITP`, adults and children ≥ 6 years, where it will now compete with [HUTCHMED’s newly approved SYK inhibitor sovleplenib / SYVIK](https://chinapharmadesk.com/hutchmed-sovleplenib-china-itp-waiha-approval/)), immunosuppressant-refractory severe aplastic anemia (`SAA`), first-line `SAA` ( ≥ 15 years) combined with immunosuppressive therapy, and chemotherapy-induced thrombocytopenia (`CTIT`) in solid tumors. Adding peri-procedural `CLD` allows Hengrui to challenge Fosun Pharma (`600196.SS` / `02196.HK`) and AkaRx’s `avatrombopag` (`Doptelet`) and Shionogi / Eddingpharm’s `lusutrombopag` (`Mulpleta`)—a global class that generated **`$2.222 billion`** in 2025 sales according to EvaluatePharma data cited in the filing.
2. **Explicit portal vein thrombosis (`PVT`) label guardrail**: Because up to 78% of cirrhotic patients suffer from thrombocytopenia alongside sluggish portal venous flow, chronic `TPO-R` over-stimulation risks portal vein thrombosis. Hengrui’s proposed indication text explicitly mandates: *“Except for application scenarios within the scope of the indication, `CLD` patients must not take this product to restore normal platelet counts.”*

---

## 2\. Dual-pathway autoimmune, renal, and retinal biologics: GenSci, Huadong, Simcere, and Xingqi

Four additional IND clearances and acceptances between November 18 and November 21 highlight how Chinese R&D teams are moving from single-target “me-too” antibodies to **bispecific pathway blockade** and **targeted protein degradation (`PROTAC`)** in non-oncology indications:

- **Changchun High-Tech / GenSci (`000661.SZ`, Notice `2026-106`) — `GenSci161` (`IL-1α` \+ `IL-1β` bispecific `IgG1`) reaches seven autoinflammatory indications**: On November 21, `NMPA` accepted two new `IND` filings for `GenSci161` in **pyoderma gangrenosum (`PG`, `CXSL2601287`)**—a rare neutrophilic ulcerative dermatosis (`3–10 cases per million/year`, where only `adalimumab` in Japan holds a specific approval globally and zero drugs are approved in China)—and **cryopyrin-associated periodic syndromes (`CAPS`, `CXSL2601288`)**, an `NLRP3` gain-of-function inflammasomopathy (`2.7–5.5 per million` prevalence spanning `FCAS`, Muckle-Wells syndrome `[MWS]`, and `NOMID/CINCA`). Unlike Novartis’s (`SIX: NOVN`) `canakinumab` (`Ilaris`), which neutralizes only `IL-1β`, `GenSci161` simultaneously neutralizes **both `IL-1α` (released as a damage-associated alarmin from necrotic epidermal and endothelial cells) and `IL-1β`**. GenSci has now amassed **seven `IND` filings** for `GenSci161`—with China `INDs` already approved in endometriosis (`EM`), hidradenitis suppurativa (`HS`), non-infectious uveitis (`NIU`), and connective tissue disease-associated interstitial lung disease (`CTD-ILD`), a U.S. FDA `IND` approved in `HS`, and a China `IND` accepted in recurrent pericarditis (`RP`)—building a rare immunology franchise to diversify Changchun High-Tech beyond somatropin growth hormone.
- **Huadong Medicine (`000963.SZ`, Notice `2026-064`) — `HDM4002` (`CFB × MASP-2` bispecific antibody) in `IgA` nephropathy**: On November 18, wholly-owned subsidiary Zhongmei Huadong received `NMPA` Phase 1 `IND` approval (`2026LP03558`, `CXSL2600971`) for `HDM4002` in adult primary `IgA` nephropathy (`IgAN`). Under the “Four-Hit” pathogenesis of `IgAN`, mesangial deposition of galactose-deficient `IgA1` (`Gd-IgA1`) immune complexes activates **both** the complement alternative pathway (driven by **Complement Factor B `[CFB]`**) and the lectin pathway (driven by `**MASP-2**`). While single-pathway agents such as Novartis’s oral `CFB` inhibitor `iptacopan` (`Fabhalta`) or Omeros’s anti-`MASP-2` antibody `narsoplimab` leave the parallel cascade unblocked, `HDM4002` is engineered to clamp both the initiation (`MASP-2`) and amplification (`CFB`) loops in a single bispecific molecule.
- **Simcere Pharmaceutical (`02096.HK`) — `SIM0712` (oral `STAT6` `PROTAC` degrader) in atopic dermatitis**: Simcere secured China `IND` clearance for `SIM0712`, an oral heterobifunctional `PROTAC` that binds the `SH2` domain of **signal transducer and activator of transcription 6 (`STAT6`)** and recruits the `CRBN` E3 ubiquitin ligase to degrade `STAT6` via the ubiquitin-proteasome system (while sparing `STAT1` and `STAT5`). Because both `IL-4` and `IL-13` receptors signal obligately through `STAT6` to drive Type 2 inflammation, `IgE` class switching, and epidermal barrier disruption, oral `STAT6` degradation aims to replicate the dual `IL-4Rα` blockade of Sanofi and Regeneron’s injectable `dupilumab` (`Dupixent`) in a once-daily capsule.
- **Shenyang Xingqi Ophthalmic (`300573.SZ`, Notice `2026-070`) — `SQ-25042` fusion-protein intravitreal injection**: On November 20, Xingqi received three simultaneous `NMPA` `IND` approvals for Class 1 fusion protein `SQ-25042` across **neovascular age-related macular degeneration (`nAMD`, `2026LP03584`)**, **diabetic macular edema (`DME`, `2026LP03585`)**, and **macular edema secondary to retinal vein occlusion (`RVO`, `2026LP03586`)**. Just one week after [Zhaoke Ophthalmology (06622.HK) won NMPA approval for its nightly 0.05% cyclosporine ophthalmic gel Jingyouling against Xingqi’s daytime Zirun](https://chinapharmadesk.com/zhaoke-cyclosporine-gel-china-dry-eye-approval/), `SQ-25042` marks Xingqi’s first expansion from anterior-segment topical drops into posterior-segment retinal biologics.
- **Export API & domestic generic clearances (`600488.SS`, `600521.SS`, `688799.SS`)**: Rounding out the week’s statutory filings, **Tianjin Tianyao Pharmaceuticals (`SSE: 600488`, Notice `2026-076`)** received a U.S. FDA Drug Master File (`DMF`) First Adequate Letter (`DMF #033893`, submitted September 2019; RMB 3.00 million R&D spend) for corticosteroid API `**betamethasone**` (`$835 million` global single-agent formulation market in 2025 per `IQVIA`); **Zhejiang Huahai Pharmaceutical (`SSE: 600521`, Notice `Lin 2026-119`)** won Class 3 generic approval (`Guoyao Zhunzi H20266613`; RMB 4.24 million R&D spend) for postoperative analgesic **`ketorolac tromethamine` injection** (`1 mL:30 mg`; RMB 88 million 1H 2026 China hospital sales); and **Hunan Warrant Pharmaceutical (`SSE: 688799`, Notice `2026-070`)** won Class 4 generic approval (`Guoyao Zhunzi H20266646`, `CYHS2501454`) for gastric mucosal protectant **`teprenone` capsules** (`50 mg`).

---

## 3\. Dual Guangxi compliance crackdown: Zhongheng’s RMB 796.8m revenue reversal and Yulin Pharma’s 8-item FDA Form 483

In sharp contrast to the clinical pipeline milestones above, two established pharmaceutical manufacturers headquartered in **Guangxi Province**—state-backed **Guangxi Wuzhou Zhongheng Group (`600252.SS`, maker of `Xueshuantong` freeze-dried panax notoginseng saponins)** and Consun Pharmaceutical (`01681.HK`) subsidiary **Guangxi Yulin Pharmaceutical (maker of `Zhenggushui` and `Shiduqing`)**—became the focus of domestic securities and U.S. FDA `cGMP` enforcement on November 20 and 21.

### CSRC Guangxi Bureau Warning Letter `[2026] No. 23` at Zhongheng Group (`600252.SS`): Gross-to-net inflation and suspected criminal distribution fraud

On November 21 (`Lin 2026-97`), Zhongheng Group disclosed that on November 20 it received Administrative Regulatory Measure Decision `**[2026] No. 23**` from the `CSRC` Guangxi Bureau, issuing a formal Warning Letter (`Jingshihan`) and Integrity Archive record against the company, current Chairman **Yang Jinhai**, and former CFO **Ge Hui** for improper asset-impairment accounting and inaccurate revenue-recognition methods across **2023, 2024, and 2025**.

Cross-referencing `Lin 2026-97` with Zhongheng’s [prior restatement filing (1225022354.PDF, March 21, 2026)](https://static.cninfo.com.cn/finalpage/2026-03-21/1225022354.PDF?ref=chinapharmadesk.com) and its [Shanghai Stock Exchange Annual Report Inquiry Reply (Lin 2026-58, July 8, 2026)](http://static.sse.com.cn/disclosure/listedinfo/announcement/c/new/2026-07-08/600252%5F20260708%5F4CK3.pdf?ref=chinapharmadesk.com) exposes the exact mechanics of how traditional Chinese medicine (`TCM`) companies inflate top-line distribution revenue when core injectable hospital volumes come under procurement pressure:

1. **RMB 704.14 million in improper gross-method (`Zong'efa`) revenue booking**: Under China Accounting Standard No. 14 (`CAS 14 Article 34`), a distributor may book full gross revenue (`principal` basis) only if it takes physical control, inventory risk, and pricing authority before transferring goods; otherwise, it must book only the net agency fee (`net` basis). Between 2023 and 3Q 2025, Zhongheng booked API, *ejiao* (donkey-hide gelatin), non-stocked *sanqi*/*dilong* herbal trades, and drop-shipped health foods, household chemicals, and medical devices—where suppliers shipped directly to customers without Zhongheng handling logistics or retaining bills of lading—on a **100% gross basis**, including trades with overlapping customer-supplier counterparties. Following regulatory scrutiny, Zhongheng was forced to restate those trades to a net basis, wiping out **RMB 127.89 million** of reported revenue in FY2023, **RMB 166.06 million** in FY2024, and **RMB 410.18 million** in 9M 2025 (**RMB 704.14 million cumulative**).
2. **RMB 92.66 million in reversed wholesale trades referred to Economic Crime Police (`Jingzhen`)**: Even more damaging, Zhongheng’s distribution subsidiary `Guangtou Pharmaceutical` (`Guangxi Investment Pharmaceutical`) booked **RMB 92.66 million** in 9M 2025 gross pharmaceutical sales (and RMB 87.22 million in unpaid receivables) across **five regional wholesalers all introduced by the exact same intermediary**:
  - `Guangxi Qucaotang Pharmaceutical Logistics`: **RMB 32.57 million** net revenue (`RMB 36.80m` tax-inclusive; `RMB 24.73m` unpaid balance; sourced from `Guangxi Jointown`);
  - `Guangxi Haixing Pharmaceutical` (formerly `Guangxi Neptunus Galaxy`): **RMB 17.73 million** (`RMB 19.34m` unpaid; sourced from `Guangxi Jointown`);
  - `Guangxi Du'an Jianxing Pharmaceutical`: **RMB 16.75 million** (`RMB 18.92m` unpaid; circularly sourced from `Qucaotang`, `Fudi Huaren`, `Sinopharm Guangxi`, and `Haixing`);
  - `Guangxi Fudi Huaren Pharmaceutical`: **RMB 15.24 million** (`RMB 12.03m` unpaid); and
  - `Yunnan Pharmaceutical Technology Development`: **RMB 10.38 million** (`RMB 10.19m` unpaid).

When `Qucaotang` defaulted in 2025 and `Guangtou Pharmaceutical` filed a civil collection lawsuit, **both first- and second-instance courts dismissed the civil suit on grounds of suspected criminal contract fraud** and ordered the case transferred on **May 12, 2026** to the **Nanning Public Security Bureau Jiangnan Branch Economic Crime Investigation Brigade**—forcing Zhongheng to reverse the entire **RMB 92.66 million** in revenue (and RMB 1.84 million in net profit) and triggering two successive `CSRC` warning letters (`[2026] No. 5` in June and `[2026] No. 23` on November 20).

### U.S. FDA Form 483 at Guangxi Yulin Pharmaceutical (8 Observations) and Daiichi Sankyo Europe (3 Observations)

While `CSRC` policed financial reporting in Wuzhou, newly released U.S. FDA Form 483 inspection reports highlighted quality-system breakdowns at **Guangxi Yulin Pharmaceutical Group** (a subsidiary of Hong Kong-listed Consun Pharmaceutical `01681.HK`; inspected March 17–21, 2025, with an 8-observation Form 483 issued to Chairman Guo Guorong) and **Daiichi Sankyo (`TSE: 4568`) Europe’s formulation plant** (inspected July 14–18, 2025; 5-page amended Form 483 with 3 observations):

| Facility & Inspection Window                                                            | Cited 21 CFR Part 211 / cGMP Observation                                                | Operational & Regulatory Detail Verified in Form 483                                                                                                                                                                                                                                                                                                                                                    |
| --------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Guangxi Yulin Pharmaceutical** (Consun 01681.HK, Mar 17–21, 2025; **8 observations**) | **Obs. 5 — Continued Production in Decommissioned Tank (211.100(b))**                   | After receiving a formal notice to **stop using Formulation Tank #4**, the plant failed to open a deviation or suitability evaluation and **continued manufacturing batches in Tank #4 for 7 consecutive months** until replacement; **100% of those batches were exported to the U.S.**                                                                                                                |
| **Guangxi Yulin Pharmaceutical**                                                        | **Obs. 1 & Obs. 3 — OTC Release & Stability Without Assay (211.165(a) / 211.166(a))**   | Exported OTC drug batches were released to the U.S. market **without testing active-ingredient concentration against labeled % specs** (reporting mg/mL without verifying label %), and lacked any written stability-testing protocol or stability-indicating assay                                                                                                                                     |
| **Guangxi Yulin Pharmaceutical**                                                        | **Obs. 2 — Data Integrity & Missing Audit Trails (211.160(b))**                         | Analytical laboratory software **lacked electronic audit trails**, allowing QC personnel to **freely delete raw analytical data**; test methods were unvalidated and internal standards conflicted with the *Chinese Pharmacopoeia*                                                                                                                                                                     |
| **Guangxi Yulin Pharmaceutical**                                                        | **Obs. 4, 6, 7 & 8 — 2016 Vendor Audits, Cleaning & Yield (211.84 / 211.67 / 211.125)** | **Most recent API supplier audit record dated back to 2016** (9-year gap) with SOP edits bypassing change control (Obs. 7); unvalidated batch-size yield limits (Obs. 4), unvalidated cleaning hold times (Obs. 6), and missing packaging label reconciliation (Obs. 8)                                                                                                                                 |
| **Daiichi Sankyo Europe Formulation Plant** (July 14–18, 2025; **3 observations**)      | **Obs. 1, 2 & 3 — Uncontrolled Empower Manual Integration & OOS Invalidation**          | Laboratory lacked an SOP governing **Empower chromatography manual integration**, with widespread manual peak re-integration performed without justification, authorization, or audit-trail review (Obs. 1); two content-uniformity OOS results invalidated without analyst interviews (Obs. 2); visible material residue on gaskets and chipped tablet punches on equipment logged as cleaned (Obs. 3) |

For global supply-chain and quality teams, Yulin Pharmaceutical’s eight-item Form 483—combining seven months of production in a red-tagged vessel with raw data deletion and a nine-year gap in API vendor audits—carries a high probability of escalating into an **FDA Import Alert (`66-40`, detention without physical examination of unapproved/cGMP-deficient drugs)** or a formal Warning Letter in late 2026 or early 2027.